Lymphomas and Leukaemias Webinar
View live online 28 April 28, 1.00am (AEST) or on demand after.
Leukaemia and lymphoma are haematologic neoplasms that affect members of all age groups. Each year, over 140,000 people in the US are diagnosed with a haematologic malignancy of some kind.
With constant advancement of treatment options, the importance of accurate diagnosis and detection of lymphomas and leukaemias becomes more and more relevant to the survival of the patient, and immunohistochemistry has served as a key auxiliary test in determining these diagnoses. This presentation covers many of the basic science, facts, and statistics of haematologic malignancies, as well as the utility of immunohistochemical testing with markers such as CD20, PAX-5, CD61, CD71, Cyclin D1, and SOX-11 in the accurate diagnosis and survival rates of lymphoma and leukaemia.
What Will You Learn?
- The advancements in immunohistochemical methods that enhance haematopathology
- The pathology of lymphoma and leukaemia
- Innovative detection biomarkers including SOX-11, PAX-5, and CD71
- Demonstration of advanced staining on clinical samples
Who Should Attend?
- Medical Directors
- Lab Managers
- Lab Technicians
- Residents/Histotech Students
- Health Care Professionals
|Jeff Gordon is the OEM Sales Manager for Millipore Sigma Tissue Diagnostics. He has a Bachelor of Science in Microbiology from the University of Arkansas. In his over 17 years in the diagnostic Immunohistochemistry industry, he has served as a technical consultant managing territories covering most of the United States and Canada, as International Sales Manager, and as the Director of Sales and Marketing for Cell Marque before transitioning to OEM Sales Manager as part of the Millipore Sigma corporation. His roles have involved sales, marketing, customer care/complaint handling, and product development. He has given over 60 IHC-related workshops and webinars at a local, state, national, and international level.|